High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

IntroductionThis study aims to evaluate the efficacy and safety of the novel combination of Aza and HIA as the frontline induction therapy in newly diagnosed AML patients eligible for intensive chemotherapy (IC) (registered on ClinicalTrials.gov, number NCT04248595).MethodsAza (75mg/m2/d on days1-5...

Full description

Bibliographic Details
Main Authors: Jun Li, Yanqing Huang, Yue Hou, Yan Gu, Chunhua Song, Zheng Ge
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
azacitidine
homoharringtonine
phase 2 trial
newly diagnosed
AML
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1069246/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1069246/full

Similar Items